Literature DB >> 19010373

IL-6R distribution in normal human and cynomolgus monkey tissues.

Atsuhiko Kato1, Takeshi Watanabe, Masaki Yamazaki, Toshiaki Deki, Masami Suzuki.   

Abstract

Interleukin-6 (IL-6) is a pleiotropic cytokine and a contributing factor in many diseases such as rheumatoid arthritis, Castleman's disease, Crohn's disease, and multiple myeloma. Since the blockade of the signaling pathway of the IL-6/interleukin-6 receptor (IL-6R)/gp130 complex is considered to have therapeutic value in such diseases, we developed an IL-6R humanized antibody (tocilizumab). In the current report, distribution of IL-6R in both normal human and cynomolgus monkey tissues was assessed as fundamental data to support preclinical and clinical studies of tocilizumab. Human and cynomolgus monkey tissue panels were stained with commercially available anti-human IL-6R and a species- and isotype-matched negative antibody, as well as assay control slides. The detection system applied used an Envision immunoperoxidase staining procedure with DAB reaction. Positive reactions were observed in the tissue elements of lymphatic, hematopoietic, digestive, reproductive, exocrine, endocrine, neural, muscular, epidermal, respiratory, and urinary systems of the human and cynomolgus monkey tissue panels. The current report is inclusive of a wide variety of tissues and shows the distribution of IL-6R to be similar for both human and monkey tissues. We consider this information fundamental for the support and interpretation of preclinical and clinical studies of anti-IL-6R antibody therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010373     DOI: 10.1016/j.yrtph.2008.10.007

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.

Authors:  Patrick M Glassman; Yang Chen; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-12       Impact factor: 2.745

2.  Neuropil pruning in Early-Course Schizophrenia: Immunological, Clinical, and Neurocognitive Correlates.

Authors:  Konasale M Prasad; Ashley M Burgess; Matcheri S Keshavan; Vishwajit L Nimgaonkar; Jeffrey A Stanley
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-11

3.  Differential susceptibility of white matter tracts to inflammatory mediators in schizophrenia: an integrated DTI study.

Authors:  Konasale M Prasad; Catherine H Upton; Vishwajit L Nimgaonkar; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2014-10-22       Impact factor: 4.939

4.  Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling.

Authors:  Janne K Nieminen; Mirja Niemi; Taina Sipponen; Harri M Salo; Paula Klemetti; Martti Färkkilä; Jukka Vakkila; Outi Vaarala
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

5.  Tissue-specific effects of an anti-desmoglein-3 ADCC antibody due to expression of the target antigen and physiological characteristics of the mouse vagina.

Authors:  Etsuko Fujii; Shinichi Funahashi; Kenji Taniguchi; Shigeto Kawai; Kiyotaka Nakano; Atsuhiko Kato; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2019-12-19       Impact factor: 1.628

6.  Anti-Thy-1 Antibody-mediated Complement-dependent Cytotoxicity is Regulated by the Distribution of Antigen, Antibody and Membrane Complement Regulatory Proteins in Rats.

Authors:  Chie Kato; Atsuhiko Kato; Kenji Adachi; Etsuko Fujii; Kaori Isobe; Tomochika Matsushita; Takeshi Watanabe; Masami Suzuki
Journal:  J Toxicol Pathol       Date:  2013-04-22       Impact factor: 1.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.